Table 1.
Demographic and clinicopathological characteristics of COVID-19 patients and controls.
| Variable group | COVID-19 patients |
Control (n = 50) (Mean ± SD) |
||
|---|---|---|---|---|
| Mild & Moderate (n = 98) (Mean ± SD) |
Severe & Critically severe (n = 52) (Mean ± SD) |
Total (n = 150) (Mean ± SD) |
||
| Age (yrs) | 48.36 ± 9.14 | 50.40 ± 9.06 | 49.43 ± 9.10 | 45.80 ± 8.82 |
| Gender (n (%)) Male Female |
56 (57.2%) 42 (42.8%) |
33 (63.5%) 19 (36.5%) |
89 (59.3%) 61 (40.7%) |
32 (64%) 18 (36%) |
| Mortality (n (%)) | 9 (9.2%) | 17 (32.7%) | 26 (17.3%) | – |
| AST (U/L) | 33.15 ± 21.97 | 38.28 ± 37.65⁎, a | 31.12 ± 31.12 | 22.05 ± 9.37 |
| ALT (U/L) | 34.44 ± 23.56⁎, a | 35.0 ± 30.79⁎, a | 34.73 ± 27.42⁎, a | 19.35 ± 7.71 |
| Urea (mg/dl) | 40.71 ± 14.48⁎, a | 41.35 ± 15.20⁎, a | 41.05 ± 14.77⁎, a | 32.05 ± 6.57 |
| Creatinine (mg/dl) | 1.22 ± 0.35⁎, a | 1.18 ± 0.34⁎, a | 1.20 ± 0.34⁎, a | 0.93 ± 0.22 |
| CRP (mg/dl) | 75.04 ± 39.50⁎⁎, a | 78.97 ± 23.31⁎⁎, a | 77.10 ± 31.88 ⁎⁎, a | 4.99 ± 1.57 |
| WBCs (10^3/μl) | 10.03 ± 4.17⁎, a, ⁎⁎, c | 14.38 ± 6.06⁎⁎, a, b | 12.32 ± 5.66⁎⁎, a | 7.47 ± 2.05 |
| Neutrophils (%) | 73.76 ± 7.19⁎⁎, a, c | 79.26 ± 5.57⁎⁎, a, b | 76.65 ± 6.92⁎⁎, a | 65.00 ± 5.06 |
| Lymphocytes (%) | 19.89 ± 6.94⁎⁎, a, c | 14.21 ± 5.13⁎⁎, a, b | 16.91 ± 6.66⁎⁎, a | 29.60 ± 5.30 |
| D-dimer (mg/L) | 0.43 ± 0.35⁎⁎, c | 2.64 ± 3.34⁎⁎, a, b | 1.59 ± 2.66⁎, a | 0.06 ± 0.01 |
| Ferritin (ng/ml) | 213.86 ± 135.24⁎, a, ⁎⁎, c | 494.11 ± 260.96⁎⁎, a, b | 361.0 ± 252.47⁎⁎, a | 104.35 ± 50.85 |
| SAA (ng/ml) | 105.57 ± 17.32⁎⁎, a, c | 171.89 ± 51.96⁎⁎, a, b | 140.39 ± 51.50 ⁎⁎, a | 11.94 ± 8.69 |
| IP-10 (pg/ml) | 260.81 ± 79.02⁎⁎, a, c | 405.0 ± 85.27⁎⁎, a, b | 336.51 ± 109.30⁎⁎, a | 92.63 ± 29.20 |
⁎
Significant at p-value < 0.05.
⁎⁎
Highly significant at p-value < 0.001.
a
Significant difference versus Control group.
b
Significant difference versus Moderate group.
c
Significant difference versus Severe group.